Dr Rina Hui

Dr Rina Hui is a specialized medical oncology practice and clinical research entity led by Clinical Professor Rina Hui, based in Sydney, Australia. The entity is primarily focused on thoracic oncology and has played a pivotal role in the clinical development of major immunotherapies, including pembrolizumab and durvalumab. Dr. Hui is a globally recognized key opinion leader who has served as a principal investigator on landmark clinical trials such as KEYNOTE-024 and PACIFIC, which have redefined the standard of care for non-small cell lung cancer. Operating through the Crown Princess Mary Cancer Centre at Westmead Hospital, the practice integrates high-level patient care with cutting-edge research in checkpoint inhibition and targeted therapies. The entity collaborates extensively with major pharmaceutical companies and academic institutions, including the University of Sydney, to advance the treatment of lung and breast cancers.